Navigation Links
B-Cell Biologic Therapy Could Revolutionize Rheumatoid Arthritis Treatment

Biologic therapy directed at B-cells could turn out be more effective in the treatment of rheumatoid arthritis, a chronic inflammatory disease arising out of an auto immune disorder.//

An international study conducted on Rituximab, a form of biologic therapy for treatment of rheumatoid arthritis has been found to achieve remission in rheumatoid arthritis patients who exhibit resistance to conventional DMARDs. The effect, independent of steroid administration is seen despite the variability in the dosage of the drug.

Drugs aimed at suppressing inflammation-provoking cytokines--specifically those linked to T-cells--have improved the treatment of rheumatoid arthritis (RA). Still, the frequency of remission achieved by these biologic agents remains below 50 percent. To increase the success rate of biologic therapy for RA patients, researchers have honed in on a new target: the B cell.

Rituximab, a biologic agent that selectively depletes B cells, has been successfully used to treat non-Hodgkin's lymphoma. It has also been shown to improve disease symptoms for RA patients, when injected at aggressive levels for a two-week period. To investigate this biologic's potential long-term therapeutic value, an international team of scientists set out to compare the effectiveness and safety of different rituximab doses over a 24-week period, with and without steroids. Their study focused on 465 RA patients with moderate to severe symptoms resistant to disease-modifying antirheumatic drugs (DMARDs), including other biologics. The results, featured in the May 2006 issue of Arthritis & Rheumatism.

Drawn from outpatient populations in California, Texas, Arizona, Switzerland, Sweden, Poland, and England, the subjects were randomly divided into nine treatment groups. Three groups received a 1,000-mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a 50 0 mg. dose of rituximab--two infusions two weeks apart--with either intravenous steroid, oral steroid, or placebo. Three groups received a placebo with either intravenous steroid, oral steroid, or another placebo. All subjects received the DMARD methotrexate (MXT). All subjects were evaluated every four weeks for changes in the Disease Active Score (DAS), a 28-joint assessment for swelling and tenderness, as well as for overall disease improvement, with the goal of meeting the American College of Rheumatology (ACR) 20 percent improvement criteria.

At the 24-week culmination, 54 percent of the subjects in three rituximab 1,000 mg. X 2 groups and 55 percent of the subjects in the three rituximab 500 mg. X 2 groups had achieved the desired ACR20 response, compared with 28 percent of the subjects in the three placebo groups. The different dosages of rituximab did not have a statistically significant impact on the odds of achieving an ACR20 response, and analyses of the proportions of patients who achieved higher ACR improvement scores--50 percent and 70 percent--showed similar patterns. Changes in DAS28 at week 24 reflected the ACR response findings, as did the subjects reports of relief from joint pain and stiffness. What's more, subjects in the rituximab groups showed gains toward disease remission earlier in the course of treatment than subjects in the placebo group.

Steroids, whether received intravenously or orally, showed no significant correlation with disease improvement scores among the rituximab groups. Intravenous steroid, however, showed a positive correlation to improved tolerability during the first rituximab infusion in both dosage groups. Overall, adverse events associated with rituximab were mild and easily managed. Headache was the most common complaint.

Confirming the role of B cells in the inflammatory processes behind RA, this study demonstrates the effectiveness and safety of a unique biologic therapy, in moderat e doses and independent of steroids. Yet, as its leading author, Dr. Paul Emery, notes, further studies are needed before applying the results to the routine treatment of RA patients. 'Both doses of rituximab explored in this study warrant further differential exploration and longer-term follow-up,' he stresses.


'"/>




Related medicine news :

1. Smallpox as Biological Weapons?
2. Biologicals Transfer Proposal between US and Indian Biotechnology
3. Novel Biological Pacemaker Under Construction for Weak Hearts
4. Biologically Women Are More Vulnerable To HIV Infection
5. Biological Clock Could Be Re-Set: Study
6. Gold Nanoparticles Are Good Detectors Biological Toxins
7. Sunglasses Can Really Pull a Fast One on the Biological Clock, and Set a Lag in the Build Up Of Jet Lag
8. Can Men Gauge Biological Paternity Accurately
9. Biological Basis for Homosexuality
10. Biological Basis Behind a Couch Potato
11. Artificial Light May Damage Biological Clock In Premature Babies
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/12/2016)... ... February 12, 2016 , ... Miami Dental Specialists is ... to their Miami dental office. Beginning in January, Miami Dental Specialists will offer the ... Specialists are the first office to be chosen by the dental implant manufacturer, Straumann, ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... surrounding communities by continuing it’s commitment to act as Agents of Change in ... works closely with area homeless families to fulfill immediate needs and help them ...
(Date:2/12/2016)... ... 12, 2016 , ... Nearly every health website and vision ... articles generally list between five and 15 foods that should be consumed regularly ... of these lists and believes that nutritious eye healthy foods are extremely important, ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a ... CertainTeed, North America’s leading brand of building products, has improved upon its industry-best ... the mobile version of the ColorView® Exterior Style and Color Selector. Created expressly ...
(Date:2/12/2016)... Ranch, Colo. (PRWEB) , ... February 12, 2016 , ... ... over the past 35 years. A president has access to health and wellness resources ... of the free world, no single individual has a schedule as frenetic as the ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... -- The primary goal of this research is to ... usage of liquid biopsy. Key information the survey seeks ... of liquid biopsy adoption amidst future users - Predominantly ... - Sample inflow to conduct liquid biopsy tests - ... so on. - Correlation analysis of sample type and ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
Breaking Medicine Technology: